Tag: Motley Fool

The All Ordinaries index has started 2024 positively and is up almost 2% year to date.

But as positive as that it is, it pales in comparison to some of the gains that have been made on the index.

For example, the three ASX All Ords shares listed below are up at least 60% since the start of the year. Here’s why investors have been scrambling to buy them:

Life360 Inc (ASX: 360)

The Life360 share price is up 63% in 2024. The catalyst for this was a stronger than expected FY 2023 result and excitement over its outlook.

Life360’s reported adjusted EBITDA of US$20.6 million for the year, which was well ahead of its guidance range of US$12 million to US$16 million. Looking ahead, in FY 2024, management expects adjusted EBITDA in the range of US$30 million to US$35 million. This represents 45% to 70% growth year on year. It also announced plans to expand into the advertising market.

Megaport Ltd (ASX: MP1)

The Megaport share price is up 64% since the start of the year. Investors were fighting to get hold of the elasticity connectivity and network services interconnection provider’s shares following the release of its quarterly update.

For the three months, Megaport reported total revenue of $48.6 million. This was an increase of 5% quarter on quarter and 31% year on year. This underpinned a strong turnaround in profitability while still investing in growth, with Megaport reporting positive EBITDA of $15.1 million for the quarter.

Zip Co Ltd (ASX: ZIP)

The Zip share price is up an incredible 92% year to date. This was driven by a strong first-half performance and rumours that the buy now pay later provider could be a takeover target.

In respect to its performance, in January the company released its second quarter update and reported an 8.5% lift in transaction value over the prior corresponding period to $2.8 billion.

And thanks to an improvement in its revenue margin to 8.2%, Zip’s revenue was up 26.1% to $225.6 million for the quarter. This ultimately led to the company achieving positive first-half cash EBTDA of $30.8 million, from negative $33.2 million a year earlier.

The post Guess which 3 ASX All Ords shares are up 60%+ in 2024 appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Goldman Sachs says these ASX tech stocks are top buys
• Long-term investing: 3 top ASX stocks you can buy for under $20 a share
• Top brokers name 3 ASX shares to buy next week
• Here are the top 10 ASX 200 shares today
• Brokers name 3 ASX shares to buy now

Motley Fool contributor James Mickleboro has positions in Life360. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Megaport, and Zip Co. The Motley Fool Australia has recommended Megaport. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/PdvZN4k

If you haven’t heard the investing parable of Mr Market, today is a great time to correct that injustice. It’s a story first told by legendary investor Benjamin Graham, but popularised by his even more legendary disciple, Warren Buffett.

In this parable, Graham describes the nature of a personified stock market (Mr Market) and how investors should take advantage of it without falling for the traps that it sets out for us.

Here’s some of how Warren Buffett laid it out back in 1987:

Without fail, Mr Market appears daily and names a price at which he will either buy your interest or sell you his. Even though the business that the two of you own may have economic characteristics that are stable, Mr Market’s quotations will be anything but. For, sad to say, the poor fellow has incurable emotional problems…

Under these conditions, the more manic-depressive his behavior, the better for you. But… Mr Market is there to serve you, not to guide you. It is his pocketbook, not his wisdom, that you will find useful. If he shows up some day in a particularly foolish mood, you are free to either ignore him or to take advantage of him, but it will be disastrous if you fall under his influence.

By “falling under his influence”, Buffett refers to the tendency that some investors have to take the prices the stock market gives us to heart.

Many investors become terrified when they see shares of a company they own plunge in value. This might even prompt them to sell those shares for a huge loss, just to avoid the pain of seeing them fall even further in value.

Similarly, investors can also let greed get the better of them. Seeing a stock euphorically rocket higher can prompt a feeling of acute ‘fear of missing out’ and elicit someone to buy the now expensive shares when they probably wouldn’t have done so before.

As Buffett says, falling for these traps is often “disastrous”.

‘Mr Market’ is there to serve, not guide

That’s also the view of renowned AMP chief economist Dr Shane Oliver. In a recent edition of ‘Oliver’s Insights’, Oliver points to Warren Buffett’s warning, “Remember that the stock market is a manic depressive”, as a key insight to keep in mind in the current environment.

Here’s some more of what he told ASX investors:

Rules of logic often don’t apply in investment markets. The well-known advocate of value investing, Benjamin Graham, coined the term ‘Mr Market’ (in 1949) as a metaphor to explain the share market.

Sometimes Mr Market sets sensible share prices based on economic and business developments. At other times he is emotionally unstable, swinging from euphoria to pessimism. But not only is Mr Market highly unstable, he is also highly seductive – sucking investors in during the good times with dreams of riches and spitting them out during the bad times when all hope seems lost.

Investors need to recognise this.

Similarly, Oliver also quotes the influential economist John Maynard Keynes’ advice that “Markets can remain irrational longer than you can remain solvent”.

Oliver warns investors that you can’t rely on personal predictions of what Mr Market will, or should, do at any point. Making huge bets that may ruin your finances if wrong is not a good way to go about investing.

It just goes to show how important sticking to timeless principles of success like diversification, apathy towards what others are doing, and long-term thinking is in today’s modern world.

The post Are you still trying to time Mr Market? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Bell Potter names the best ASX shares to buy in March
• With a spare $500, here’s how I’d start buying ASX shares this March
• Analysts say these ASX All Ords dividend stocks are buys in March
• Why 4DMedical, Block, Judo, and Mesoblast shares are pushing higher today
• What’s happening with ASX uranium shares today?

Motley Fool contributor Sebastian Bowen has positions in Berkshire Hathaway. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Berkshire Hathaway. The Motley Fool Australia has recommended Berkshire Hathaway. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/1qUCSM7

Do you have room in your portfolio for some new ASX shares?

If you do, then it could be worth checking out the two named below that Bell Potter has on its monthly preferred list.

Here’s why the broker thinks they are among the best buys on the local market right now:

GUD Holdings Limited (ASX: GUD)

The diversified products company could be an ASX share to buy in March. Bell Potter has been impressed with GUD’s performance recently and appears confident that more of the same is coming. Particularly given the resilience of its auto business. It said:

[Its strong result] was driven by the better-than-expected APG performance (the highest-quality business in GUD, in our view) and the improvement in gearing. We see GUD as well-placed to benefit from the ongoing improvement in OEM supply constraints into FY24. Overall, our Buy rating for GUD is predicated on the relative resilience of the legacy auto business and improving momentum in new car sales, which should be favourable for APG’s earnings.

Bell Potter has a buy rating and $12.80 price target on the company’s shares.

ResMed Inc. (ASX: RMD)

Another ASX share that Bell Potter is bullish on in March is sleep disorder treatment company ResMed. It believes the company still has a very long runway for growth, which could make it a great long term option for investors. It explains:

The market for OSA and chronic obstructive pulmonary disease (COPD) remains under penetrated, and we expect industry volume growth to continue in the 6-8% range for the foreseeable future. In this regard, the competitive dynamics are very much in favour of RMD due to the Philips recall and improving semiconductor availability. […] Furthermore, ResMed is well-positioned to build on its dominant share even after Philips returns to the global market, with the launch of its latest continuous positive airway pressure (CPAP) device, the Air Sense 11.

Bell Potter has a buy rating and $34.00 price target on this ASX share.

The post Bell Potter names the best ASX shares to buy in March appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Up 37% from their low: Can ResMed shares keep rising?
• 3 reliable ASX shares you can buy at a discount
• Here are the top 10 ASX 200 shares today
• Morgans names more of the best ASX 200 shares to buy in March
• 2 classic ASX 200 shares you can buy for cheap now to hold for years

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/zmLIDcK

With just $500, anyone can make a good move for growing their wealth with ASX shares.

If I were starting to invest, I’d want to choose quality businesses that I am familiar with but also have the potential to deliver good returns.

The share market has returned an average of around 10% per annum, which is a good rate of compounding growth.

Many brokers in Australia require a minimum investment of $500 the first time we invest in an ASX share. So, let’s see what we can do with that.

Vanguard MSCI Index International Shares ETF (ASX: VGS)

It can be hard to choose one business to own when there are some many out there. So, why not (indirectly) own more than 1,400 in a single purchase? The VGS ETF held shares in 1,433 businesses in its portfolio at the end of January 2024. That’s a lot of diversification!

We can own many of the world’s leading technology businesses with an investment in this exchange-traded-fund (ETF), including Apple, Microsoft, Alphabet, Nvidia, Amazon.com, Meta Platforms and Tesla.

I believe this is the sort of investment that we can own forever because of how diversified it is, the quality of those businesses and the good returns it typically makes (though nothing is guaranteed). Over the years, the holdings are regularly updated, ensuring the ASX ETF is always invested in leading businesses.

It has an annual management fee of 0.18%, and it has achieved an average return per annum of 12.4% since it started in November 2014.

While US shares make up around 71% of the portfolio, there are numerous other countries with a noticeable weighting, including Japan, the United Kingdom, France, Canada, Switzerland, Germany and the Netherlands.

Wesfarmers Ltd (ASX: WES)

For investors wanting to own a specific ASX share, I think Wesfarmers Ltd (ASX: WES) is a great choice.

The ASX retail conglomerate operates Kmart, Bunnings, Officeworks, Priceline and many other businesses across the chemicals, energy, fertilisers, industrial and healthcare sectors.

The company has proven to be a solid performer. Bunnings and Kmart Group both earn strong returns on capital (ROC), while the overall business earns an impressive return on equity (ROE).

Wesfarmers aims to generate good total shareholder returns (TSR) for investors through a combination of capital growth and dividends.

According to CMC Markets, Wesfarmers shares have delivered an average TSR of 14% per annum over the past decade, though past performance is not a guarantee of future performance. Having said that, I think the ASX share is very capable of outperforming the S&P/ASX 200 Index (ASX: XJO) over the next five years.

The post With a spare $500, here’s how I’d start buying ASX shares this March appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 4 ASX ETFs for smart investors
• Are you investing or gambling?
• 2 fantastic ASX ETFs to buy for global investing in March
• 3 things about Wesfarmers stock every smart ASX investor knows
• 5 ASX shares to buy for an effortless path to financial freedom

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, Tesla, and Wesfarmers. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended Alphabet, Amazon, Apple, Meta Platforms, Nvidia, and Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/iV4k0Dt

The great news for income investors is that there are plenty of ASX All Ords dividend stocks to choose from on the Australian share market.

But which ones could be buys in March?

Let’s take a look at two that have been named as buys this month:

Dexus Convenience Retail REIT (ASX: DXC)

Dexus Convenience Retail REIT could be an ASX All Ords dividend stock to buy in March.

It is a real estate investment trust that owns high quality service stations and convenience retail assets.

The team at Bell Potter thinks the company is a buy. Its analysts highlight that they “see clear price discovery for DXC where there have been 53 petrol station transactions in CY23, proving up book value.”

The broker has a buy rating and $3.00 price target on its shares.

Bell Potter is forecasting dividends per share of 20.7 cents in FY 2024 and 21.7 cents in FY 2025. Based on its current share price of $2.70, this equates to yields of 7.7% and 8%, respectively.

Transurban Group (ASX: TCL)

Transurban could be another ASX All Ords dividend stock to buy now. It is the toll road operator behind roads such as CityLink and Cross City Tunnel.

Citi currently has a buy rating and $15.90 price target on Transurban’s shares.

In addition, its analysts “believe TCL’s FY24 DPS guidance of 62c is conservative.” Instead, the broker is forecasting dividends per share of 63 cents in FY 2024 and then 65 cents in FY 2025. Based on the current Transurban share price of $13.45, this will mean yields of 4.7% and 4.8%, respectively.

The post Analysts say these ASX All Ords dividend stocks are buys in March appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Bell Potter says these ASX 200 stocks are strong buys for March
• 2 buy-rated ASX dividend stocks for income investors in March
• 2 ASX 200 dividend shares that could be strong buys this month
• 3 all-star ASX dividend stocks I’d own in retirement to combat falling interest rates
• 5 ASX 200 shares that boosted their dividends this earnings season

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Transurban Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/VfWyHe8

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and dropped deep into the red. At the time of writing, the benchmark index is down 1.4% to 7,736 points.

Four ASX shares that are not letting that hold them back today are listed below. Here’s why they are rising:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is up 3% to 81 cents. This follows news that US President Biden has signed a six-bill, US$460 billion package on Saturday, approving full-year funding for the Department of Veterans Affairs among other offices. The new funding will include screening technologies, which 4DMedical could benefit from greatly.

Block Inc (ASX: SQ2)

The Block share price is up 4% to $121.58. This follows an equally strong night of trade for the payments company’s shares on Wall Street on Friday. Block’s shares have now doubled in value since the start of November.

Judo Capital Holdings Ltd (ASX: JDO)

The Judo Capital share price is up 4% to a 52-week high of $1.42. Investors have been buying this small business lender’s shares since the release of a broker note out of Goldman Sachs last week. Its analysts put a buy rating and $1.66 price target on the company’s shares. They said: “We think the market’s skepticism around the at-scale NIM focuses on the lending spread assumption of mid-4%, given the 1H24 spread was <4%.”

Mesoblast Ltd (ASX: MSB)

The Mesoblast share price is up 6.5% to 33.5 cents. This has been driven by news that the biotech company has been given a big boost from the US FDA. The federal agency revealed that it will support an accelerated approval pathway for rexlemestrocel-L under the existing Regenerative Medicine Advanced Therapy designation. It is Mesoblast’s allogeneic mesenchymal precursor cell product for patients with end-stage ischemic heart failure with reduced ejection fraction and a left ventricular assist device.

The post Why 4DMedical, Block, Judo, and Mesoblast shares are pushing higher today appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why is the Mesoblast share price jumping 16% on Monday?
• Why Judo, Paladin Energy, Virgin Money, and WA1 shares are racing higher
• Up 93% since October, why are Block shares marching ahead again on Friday?
• Why Cettire, GQG, Mesoblast, and Nine Entertainment shares are falling today
• Forget CBA and buy this ASX bank stock for big returns

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Block and Judo Capital. The Motley Fool Australia has positions in and has recommended Block. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/L7tKqNm

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares that leading brokers have named as buys this week are listed below. Here’s why they are bullish on them:

Flight Centre Travel Group Ltd (ASX: FLT)

According to a note out of Citi, its analysts have retained their buy rating and $24.15 price target on this travel agent’s shares. The broker has been reviewing the travel sector following earnings season. Flight Centre has come out of its review favourably, with the broker continuing to prefer it over its rivals. Particularly given probable corporate travel market share gains in the ANZ region. The Flight Centre share price is trading at $21.54 on Monday.

Goodman Group (ASX: GMG)

A note out of Macquarie reveals that its analysts have retained their outperform rating on this industrial property company’s shares with an improved price target of $34.89. This follows a post-earnings season review of the listed property sector. Macquarie was pleased with Goodman’s performance and highlighted the company as a top pick. Especially given its potential to deliver double-digit earnings growth over the coming years. The Goodman share price is fetching $30.47 today.

IDP Education Ltd (ASX: IEL)

Analysts at Goldman Sachs have retained their buy rating and $26.60 price target on this language testing and student placement company’s shares. Goldman acknowledges that IDP Education continues to be impacted by regulatory changes that are restricting the flow of international students. However, it points out that the company is well positioned to capitalise when conditions normalise given improving student placement market share and investments into its network and platforms. The IDP Education share price is trading at $18.85 today.

The post Leading brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• These are the 10 most shorted ASX shares
• Supercharge your portfolio with these buy-rated ASX growth shares
• 3 ASX 200 shares that could rise 20% to 50%
• Why is this ASX 200 share rising at nearly quadruple the rate of its peers?
• If you don’t own this ASX stalwart stock, you’re missing some serious stability

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Goodman Group, and Idp Education. The Motley Fool Australia has recommended Flight Centre Travel Group, Goodman Group, and Idp Education. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/9XkEpmz

The CSL Ltd (ASX: CSL) share price is down 2% in early trading as the ASX healthcare share feels the effects of the ASX stock market sell-off. CSL shares also went ex-dividend today.

On Friday in the US market, there was a sizeable decline in a number of stocks. Nvidia fell 5.5%, Eli Lilly dropped 2.3%, Microsoft declined 0.7%, Tesla fell 1.8% and so on. The S&P/ASX 200 Index (ASX: XJO) is currently down by 1.3%.

Ex-dividend day

One of the factors that may be impacting CSL shares today is that it went ex-dividend.

An ex-dividend date tells the market when new investors buying shares will miss out on the upcoming dividend. There has to be a cut-off point for deciding who will and who won’t receive the dividend.

Anyone who buys today is missing out on the interim dividend payment. Investors who bought CSL shares last week are eligible to receive the dividend, assuming they’re still shareholders on the record date (tomorrow).

How much is being paid?

CSL is going to pay a dividend of US$1.19 to shareholders, which at the time of the FY24 first-half result translated into approximately A$1.81 per share (an increase of 12%).

At the current exchange rates, the upcoming payment equates to A$1.80 per share.

CSL is expecting to release information about exchange rates for Australian and New Zealand dollar payments on 14 March 2024.

The ASX healthcare share is planning to pay this dividend on 3 April 2024, which is only a few weeks away.

CSL was able to deliver a bigger dividend after growing net profit after tax (NPAT) by 17% to US$1.9 billion in its FY24 first-half result. It also reported underlying earnings per share (EPS) growth of 11% to US$4.18.

Profit expectations

The company is expecting to report underlying NPATA of between US$2.9 billion to US$3 billion, which would be growth of between 13% to 17%.

Management thinks the business is in a strong position to deliver annualised double-digit earnings growth over the medium term.

On Commsec, the estimates imply the CSL share price is currently valued at 30 times FY24’s estimated earnings. It could pay an annual dividend of A$4, according to Commsec, which puts the forecast forward dividend yield at 1.4%.

The post Why are CSL shares falling today? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 5 things to watch on the ASX 200 on Monday
• 3 ASX shares you can confidently invest $500 in right now
• 1 ASX stock that has created millionaires and will continue to make more
• 13 ASX 200 shares with ex-dividend dates next week
• Want to grab the CSL dividend? There’s not much time left!

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Microsoft, Nvidia, and Tesla. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has recommended CSL and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/0kacY9t

The market may be tumbling on Monday but the same cannot be said for the Mesoblast Ltd (ASX: MSB) share price.

In early trade, the biotechnology company’s shares jumped 16% to 36.5 cents.

Mesoblast’s shares have eased back a touch since then but remain up approximately 7% at the time of writing.

Why is the Mesoblast share price jumping?

Investors have been bidding the company’s shares higher this morning after it released an update on its rexlemestrocel-L therapy.

It is Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product for patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD).

According to the release, following a meeting with the U.S. Food and Drug Administration (FDA) in February, it has been advised that the federal agency will support an accelerated approval pathway for rexlemestrocel-L under the existing Regenerative Medicine Advanced Therapy (RMAT) designation.

The company highlights that the FDA’s comments indicated that the presented results may support a reasonable likelihood of clinical benefit of MPCs against mortality in LVAD patients, consistent with the criteria for accelerated approval.

Mesoblast CEO, Dr. Silviu Itescu, commented:

We are very pleased with FDA’s feedback that the presented results from our pivotal study of rexlemestrocel-L in end-stage HFrEF patients with LVADs may support an accelerated approval. We intend to request a pre-Biologics License Application (BLA) meeting to discuss data presentation, timing and FDA expectations for an accelerated approval filing.

This certainly could be good news for both the company and sufferers. Mesoblast notes that every year in the United States over 100,000 patients progress to end-stage HFrEF. In these patients, more than 2,500 life-prolonging LVADs are implanted in the US annually, of whom approximately 80% undergo the procedure as destination or permanent therapy.

The Mesoblast share price is now up approximately 25% since this time last month. Though, it remains down by a sizeable 63% on a 12-month basis.

The post Why is the Mesoblast share price jumping 16% on Monday? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why Cettire, GQG, Mesoblast, and Nine Entertainment shares are falling today
• Mesoblast share price tumbles on US$32.5m half-year loss
• Guess which ASX 300 healthcare stock is surging 13% on FDA news

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/XEGChry

If you’re not averse to investing in the mining sector and are on the lookout for big returns, then it could be worth taking a closer look at one ASX 300 mining share.

That mining share is Develop Global Ltd (ASX: DVP), which is an exploration, development, and underground mining services company.

It owns two advanced Copper-Zinc projects near Port Hedland in the Pilbara region of Western Australia – the Sulphur Springs project and the Whim Creek Project.

In addition, it owns the high-grade zinc-copper-lead-gold-silver Woodlawn project in New South Wales.

Why is it an ASX 300 mining share to buy?

Bell Potter was pleased with the company’s performance during the first half, noting that its revenue was ahead of expectations. It commented:

DVP reported revenue of $65.8m was 5% ahead of our $62.5m estimate and up 162% YoY, driven by increased underground development and mining activity at the Bellevue Gold mine. Underlying EBITDA of $6.6m was lower than our $11.2m forecast and higher than -$5.1m in the prior period. This miss was due to higher-than-expected share-based payments and overheads.

Looking ahead, the broker highlights that the ASX 300 mining share is positioned well thanks to growing mining services revenue and the upcoming Woodlawn restart. It adds:

The forthcoming restart of Woodlawn operations (we expect by early CY25) coincides with growing revenue generation from the company’s underground mining services business, underpinning a ramp up in earnings FY24-26. A strong balance sheet and funds expected to be raised from deep-in-the-money options de-risks project financing for Sulphur Springs and Pioneer Dome. These developments represent medium term earnings growth drivers.

Big returns

Bell Potter has a buy rating and $4.10 price target on the company’s shares.

Based on its current share price of $2.47, this implies potential upside of 66% for investors over the next 12 months.

The post This ASX 300 mining share could deliver a 60%+ return in 2024 appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• I think these ASX stocks are bargain buys after reporting season
• Want to make big returns? ASX small-cap shares are poised to outperform
• This ASX dividend share has soared 450% in a year! Is it still a buy?
• Goldman Sachs says these ASX tech stocks are top buys
• Buy this ASX 200 biotech stock for a 20%+ return

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/7nzgDxu